Showing pharmacokinetics for Trans-Resveratrol metabolite after consumption of trans-Resveratrol in rats Metabolism
Asensi M., Medina I., Ortega A., Carretero J., Bano M.C., Obrador E., Estrela J.M. (2002) Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 33:387-98 PubMed (15736313)
Plasma analysed without enzymatic deconjugation
Show related sources from the same publication
| Plasma Concentration (µmol/L) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Number | Dose | Multiple Dose Duration | Time (minutes) |
Polyphenol Source Name as described in publication |
|||||
| 0 | 2.5 | 5 | 10 | 30 | 60 | ||||
| 1 | 20 mg/kg bw | Single Dose | 0 | 0.7 | 1.2 | 0.4 | 0.1 | 0.07 |
trans-resveratrol
|